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Rationale Atypical antipsychotics are frequently prescribed for psychotic and mood 
disorders in youth, and for symptoms of depression, aggression, irritability and suicidal 
tendencies, which are associated with subsequent  development of borderline personality 
disorders (BPD).  
Objectives This study evaluated the effects of 24-weeks of add-on treatment with 
quetiapine to selective serotonin reuptake inhibitors (SSRIs) in young people with 
pronounced symptoms of depression, aggression, irritability and suicidal tendencies.  
Methods In an open-label 24-weeks trial, 22 SSRI-treatment resistant patients (age range 
9-18 years) with developing BPD were treated with quetiapine (75-600 mg/day) in 
combination with SSRIs. Symptoms of depression, aggression, irritability and suicidal 
tendencies were rated with the Overt Aggression Scale Modified (OAS-M), Kutcher 
Adolescent Depression Scale (KADS-6) and Children Global Assessment Scale (C-GAS) 
before and after 4-24 weeks of treatment.   
Results Quetiapine induced significant (p<0.001) improvement after 4-24 weeks, with a 
modest but significant increase in the C-GAS total scores (i.e. children’s general clinical 
status), and a significant reduction of the total scores in OAS-M, KADS-6 and OAS-M 
subscales for aggression, irritability and suicidality. There were no discontinuations for 
adverse effects  
Conclusions These preliminary results suggest that quetiapine addition to SSRIs 
treatment significantly reduced symptoms of depression, aggression, irritability and 
suicidal tendencies in young people with developing BPD.  
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Atypical antipsychotics are prescribed frequently for the treatment of psychotic, 
disruptive behaviour, personality, mood and pervasive developmental disorders, 
irritability in autism and learning difficulties in children and adolescents (Adityanjee et 
al. 2008; De Hert et al. 2011; Zuddas et al. 2011). Besides serotonin reuptake inhibitors 
(SSRIs), medication used to treat borderline personality disorders (BPD) may include 
anticonvulsants, but also atypical antipsychotics (Abraham and Calabrese 2008) such as 
quetiapine (Adityanjee et al. 2008). In the Republic of Croatia, quetiapine is registered 
for treatment of psychotic and bipolar disorders in patients over 18. However, in children 
and adolescents who are refractory to treatment, and who develop various behavioural 
disorders, primarily with symptoms of BPD, the use of atypical antipsychotics is often 
regarded as necessary. The aim of this study was to evaluate the effects of 24-weeks of 
add-on treatment with quetiapine (75-600 mg/day) in patients aged 9-17 years with 
developing BPD, refractory to previous treatment, who had pronounced symptoms of 
depression, aggression, irritability and suicidal tendencies.  
The open trial included 11 male and 11 female patients 9-17 years old (mean=15.4, 
SD=1.71), admitted between 2005-2007, with hetero- or auto-aggressive (suicidal 
tendencies and suicidal thoughts), depressive and irritability symptoms, that correspond 
to symptoms in adult BPD. Since DSM-IV does not recognize a diagnosis of BPD before 
the age of 18, diagnosis was categorized as developing BPD, according to DSM-IV 
criteria, and Revised Diagnostic Interview for Borderline Patients (DIB-R). 
Refractoriness to treatment was defined when patients had the Children Global 
Assessment Scale (C-GAS) scores lower than 51 after a few treatment sessions (2 weeks 
to a few years) with SSRIs (fluvoxamine, sertraline or fluoxetine). After obtaining 
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patient’s assents and parent’s consents, patients were treated with quetiapine (average 
daily dose of 390 mg) as an add-on therapy to various SSRIs. Inclusion criteria: diagnosis 
of developing BPD, except the age criteria, IQ>90, and no positive therapeutic effect of 
SSRIs. Exclusion criteria: comorbid depressive, psychotic or eating disorders, and 
concomitant psychiatric therapy by medication other than SSRIs.  
Transient somnolence, dry mouth and fatigue were evident in some patients during the 
first 2 weeks of the trial but resolved spontaneously; no other clinical side-effects were 
recorded. None of the patients required anticholinergic medications, no discontinuation 
due to side effects was recorded, and all patients finished 24 weeks of the trial. Hospital 
monitoring was undertaken in the period of 6-8 weeks, and outpatient monitoring after 
discharge from the hospital department. The primary efficacy measure was a change from 
baseline to end point in the modified version of the Overt Aggression Scale Modified 
(OAS-M), and secondary efficacy measures were the 6-items Kutcher Adolescent 
Depression Scale (KADS-6), and the C-GAS. The study was approved by the Ethics 
Committee of the Psychiatric Hospital for Children and Youth Zagreb. The results, 
expressed as means ± standard deviations (SD), were evaluated using repeated measures 
analysis of variance (ANOVA), and Tukey’s test. The level of significance was set to 
p=0.05.  
Patients had mean DIB-R scores of 8.91 ± 0.75. Quetiapine (average dose 389.77 ± 
153.27 mg/day) treatment for 4-24 weeks significantly increased (p<0.001) the total C-
GAS scores, and significantly decreased (p<0.001) total KADS-6, total OAS-M scores, 
and scores in OAS-M aggression, irritability, and suicidality subscales (Table 1).  
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To the best of our knowledge, this is the first study to show that the add-on of quetiapine 
(average dose 390 mg/day) to SSRIs induced a significant reduction of the symptoms of 
aggression, irritability, affective instability, suicidality, and depression, and significant 
improvement in the global level of functioning in young people with developing BPD 
refractory to previous SSRI treatment. The clinical improvement remained stable over 24 
weeks of study.  
Our results are in line with the reported improvement of the combination of quetiapine 
and valproate or quetiapine monotherapy in young people with bipolar disorder (DelBello 
et al. 2006; Zuddas et al. 2011), in youth with co-morbid paediatric bipolar disorder and 
disruptive behaviour disorder (Barzman et al. 2006), and in aggressive children with 
conduct disorders (Findling et al. 2007). In contrast to our results, showing that 
quetiapine improved slightly but significantly depressive symptoms, quetiapine did not 
affect symptoms of depression in adolescents with bipolar depression (DelBello et al. 
2006). Limitations of the study were that adverse effects were not systematically 
collected and important metabolic indicators such as weight gain, fasting glucose, lipid 
levels or prolactin increase were not measured (De Hert et al. 2011).   
In conclusion, this pilot trial confirmed the clinical impression that 24-weeks of 
quetiapine treatment, added to standard SSRIs, ameliorated aggressive behaviour, 
intentional self-injury, chronic anxiety and affective instability, depression, suicidal 
tendencies and irritability in children and adolescents with developing BPD. However, 
because of its metabolic adverse effects quetiapine must be used with caution in this 
patient population and randomised trials with careful safety monitoring are needed.  
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Table 1.  Total scores in the C-GAS, KADS-6, OAS-M, and in the OAS-M subscales for 
aggression, irritability and suicidality in 22 patients (11 male and 11 female) with 
developing BPD at baseline and after 4, 8, 12, 16 and 24 weeks of treatment with 
quetiapine.  
 
 
Weeks of treatment: 
0   4 8 12 16 24 
C-GAS scores 32.5±11.9 45.0±11.9* 53.3±11.8* 48.7±8.9* 48.2±9.8* 44.5±14.9* 
ANOVA F(5, 21)=49.236; p<0.001 
KADS-6 scores 11.9±2.9 8.5±2.8* 7.1±2.7* 8.0±3.3* 7.4±3.4* 7.9±3.4* 
ANOVA F(5, 21)= 28.685;  p<0.001 
OAS-M scores 50.6±25.1 24.7±12.2* 26.4±16.2* 31.1±17.9* 29.6±17.0* 35.7±26.4* 
ANOVA F(5, 21)=23.551; p<0.001 
OAS-M 
aggression 
scores 
39.0±22.5 17.9±9.3* 19.4±13.1* 25.0±15.9* 23.2±14.2* 29.0±23.1** 
ANOVA F(5, 21)= 17.913 ; p<0.001 
OAS-M 
irritability 
scores 
7.8±1.3* 5.3±1.7* 5.6±1.7* 5.5±1.8* 5.5±2.1* 5.9±2.3* 
ANOVA F(5, 21)= 20,083; p<0.001 
OAS-M 
suicidality 
scores 
3.86±4.16 1.82±2.40* 1.45±2.38* 0.59±0.91* 0.77±1.60* 0.91±2.60* 
ANOVA F(5, 21)= 14.334; p<0.001 
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Data are presented as means ± SD. BPD= borderline personality disorder; C-GAS= 
Children Global Assessment Scale; KADS-6= Kutcher Adolescent Depression Scale; 
OAS-M= Overt Aggression Scale - Modified; OAS-M aggression= Overt Aggression 
Scale - Modified, aggression subscale; OAS-M irritability= Overt Aggression Scale-  
Modified, irritability subscale; OAS-M suicidality subscale= Overt Aggression Scale – 
Modified, suicidality subscale;  *p=0.001 vs. baseline scores; **p=0.003 vs. baseline 
scores (Tukey’s test).   
